Editas Medicine (EDIT) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Strategy and preclinical evidence

• Strategy now focused entirely on in vivo CRISPR editing; EDIT-401 makes a non-coding edit in the LDLR 3′ UTR to increase LDL receptor synthesis.

• In non-human primates, EDIT-401 reduced LDL-C by 90%, with significant Lp(a) and ApoB reductions; effects remained durable through 10 months.

• Approach directly increases LDL receptor synthesis, unlike PCSK9 inhibition, which targets receptor degradation and recycling.

Clinical development and target population

• Phase I/II Part 1 is a serial dose-escalation study, starting at a non-therapeutic dose; the protocol plans at least 3 patients per cohort across at least 4 cohorts, with potential expansion under a 3+3 design.

• GalNAc-equipped LNP delivery targets hepatocytes through ASGPR; preclinical data showed comparable efficacy in wild-type and LDLR heterozygous mice and reduced response heterogeneity.

• HeFH is the initial target; potential expansion includes very-high-risk ASCVD patients unable to reach LDL-C goals on standard care, a population estimated at ~10 million in the U.S.

• Safety and tolerability from the first cohort are expected in Q1 2027; top-line data from subsequent cohorts, including LDL-C reductions, are expected in H2 2027.

• Management aims for LDL-C reduction above 60%; a robust reduction with good tolerability could support a pivotal program initially targeting HeFH, with broader populations under consideration.

Safety and regulatory considerations

• Very low LDL-C levels were cited in genetic and clinical evidence; potential endoplasmic-reticulum stress was considered unlikely because LDLR is a low-abundance protein.

• Off-target assessment included in silico, in vitro and biochemical work, with a reported clean profile; diabetes risk will be monitored, with cited meta-analyses suggesting the risk may be near background.

• LDL-C reduction was described as the likely approval path, subject to regulatory agreement; management cited precedent for HeFH approvals based on a few hundred patients, subject to FDA views on gene editing.